Condition: Acute Respiratory Distress Syndrome · Acute Kidney Injury · Sponsor: Vantive Health LLC
PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane. The goal of this prospective, open label, randomized controlled study is to evaluate the efficacy and safety of PrismaLung+ on extracorporeal carbon dioxide removal (ECCO2R) in critically ill patients under invasive mechanical ventilation (IMV). Patients will be randomized to receive either IMV combined with ECCO2R (using PrismaLung+) in the study group or IMV alone in the control group, at a ratio of 2:1.
This description comes directly from the study's public registry record.
Global CORP Clinical Trials Disclosure · +1 2249484283 · Global.CORP.ClinicalTrialsDisclosure@vantive.com
Always discuss trial participation with your own doctor first.
| China-Japan Friendship Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The University of Hong Kong-Shenzhen Hospital | Shenzhen, Guangdong, China | Not Yet Recruiting |
| The First Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Zhongda Hospital Southeast University | Nanjing, Jiangsu, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| ZhongShan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, Sichuan, China | Not Yet Recruiting |
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07326215